通过激活PKA信号通路来抑制心力衰竭的发展
Tao Yan1, Shushuai Song2, Wendong Sun3
1Department of Cardiology, Zibo Municipal Hospital, Ward 1, No. 139 Huangong Road, Linzi District, Zibo City, Shandong Province, 255400, China.
BMC cardiovascular disorders
|April 5, 2024
概括
沉默HAPLN1通过激活PKA通路来对抗心力衰竭的进展. 这一发现为管理心力衰竭 (HF) 提供了新的治疗策略.
科学领域:
- 分子生物学分子生物学
- 心血管研究的心血管研究.
- 生物医学科学 生物医学科学
背景情况:
- 心力衰竭 (HF) 是一种广泛,复杂的疾病,其分子基础不清楚.
- 世界上有数以百万计的人受到心力衰竭的影响,这给他们的健康和经济带来了巨大的负担.
- 了解HF病变的分子机制对于开发有效的治疗方法至关重要.
研究的目的:
- 使用生物信息学识别与心力衰竭病原发生相关的关键基因.
- 为了研究HAPLN1在 ангиотензинII诱导的AC16细胞中的功能作用和HF的老鼠模型.
- 阐明HAPLN1在高频率中调节的分子通路.
主要方法:
- 生物信息查确定了关键的HF相关基因,包括HAPLN1.1.
- 试验室内实验评估了HAPLN1对安二醇治疗的AC16细胞的淘汰效应,测量了氧化应激和亡.
- 建立了体内HF大鼠模型,以评估HAPLN1对心脏功能和组织学的影响,并通过西布洛特分析途径.
主要成果:
- 鉴定出HAPLN1在HF中是一种过度表达的基因,其敲击改善了细胞活力,并在体外减少了细胞亡.
- 在大鼠HF模型中,HAPLN1敲击改善了心声学指数 (LVEF,LVFS) 和减少心脏重塑 (LVESV).
- HAPLN1 knockdown调节氧化应激标志物 (增加GSH,减少MDA,LDH) 和炎症因子 (减少TNF-α,IL-6),激活PKA通路.
结论:
- 对HAPLN1的抑制显示出对HF进展的保护作用.
- 该机制涉及PKA通路的激活,这表明了一个新的治疗点.
- 这些发现为心力衰竭的临床管理提供了新的见解.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337